Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Annals of Clinical and Translational Neurology|December 8, 2023
Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extensionRichard J Nowak, Ari Breiner, Vera Bril, et al.
Arthritis Research & Therapy|January 17, 2024
Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM studyRohit Aggarwal, Joachim Schessl, Christina Charles-Schoeman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 10, 2024
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension studyLuis Querol, Jérôme De Sèze, Tina Dysgaard, et al.
Therapeutic Advances in Neurological Disorders|July 7, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label studyMiriam Freimer, Urvi Desai, Raghav Govindarajan, et al.
European Journal of Neurology|February 13, 2023
Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg studyMamatha Pasnoor, Vera Bril, Todd Levine, et al.
Journal of the Peripheral Nervous System : JPNS|June 14, 2023
Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trialVera Bril, Robert D M Hadden, Thomas H Brannagan, et al.
European Journal of Neurology|April 18, 2025
The Results of ADVANCE-CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating PolyradiculoneuropathyMamatha Pasnoor, Colin Anderson-Smits, Todd Levine, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 6, 2025
ALSUntangled #81: Pyridostigmine (mestinon<sup>®</sup>)Nadia Mansoor, Terry Heiman-Patterson, Eva L Feldman, et al.
Muscle & Nerve|November 7, 2024
Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trialVera Bril, Tomasz Berkowicz, Andrzej Szczudlik, et al.
Muscle & Nerve|November 8, 2024
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosisSalman Bhai, Todd Levine, Dan Moore, et al.
Pageof 4